Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia

Annals of Hematology, Supplement

Volumn 84, Issue 13, 2005, Pages 39-46

  Galm, Oliver ^a   Wilop, Stefan ^a   Lüders, Christian ^a   Jost, Edgar ^a   Gehbauer, Gerald ^a   Herman, James G ^b   Osieka, Rainhardt ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myelogenous leukemia; Demethylating agents; DNA methylation; Epigenetics; Methylation profile; Tumor suppressor genes

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN P15; PROTEIN P16; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; SUPPRESSOR OF CYTOKINE SIGNALING 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; UVOMORULIN; DNA; GROWTH FACTOR; RETINOIC ACID RECEPTOR BETA2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CELL ADHESION; CONTROLLED STUDY; CPG ISLAND; CYTOGENETICS; DNA METHYLATION; EPIGENETICS; FEMALE; GENE SILENCING; GENETIC RISK; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KARYOTYPE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; APOPTOSIS; CANCER GENETICS; CARCINOGENESIS; CELL CYCLE; GENE MUTATION; GENETIC ANALYSIS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE; CHROMOSOME ABERRATION; GENETIC EPIGENESIS; GENETICS; KARYOTYPING; MIDDLE AGED; PROGNOSIS; RISK FACTOR; TUMOR GENE; CELL CYCLE ARREST; CELL CYCLE REGULATION; DRUG TARGETING; GENE DELETION; GENE FREQUENCY; GENE TARGETING; MOLECULAR GENETICS; RACE DIFFERENCE; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; GENES, NEOPLASM; HUMANS; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 29144469286     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0005-0     Document Type: Article

References (52)

1. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798-802 10029065
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann Intern Med 103:620-625 3862359
3. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691-699 10.1093/ jnci/93.9.691
4. Caligiuri MA, Strout MP, Gilliland DG (1997) Molecular biology of acute myeloid leukemia. Semin Oncol 24:32-44 9045303
5. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107 10.1038/5047
6. Cameron EE, Baylin SB, Herman JG (1999) p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 94:2445-2451 10498617
7. Claus R, Lubbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489-6496 10.1038/sj.onc.1206814
8. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59:3352-3356 10416592
9. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lubbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964 10.1182/blood.V100.8.2957
10. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082
11. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463 10.1038/ nature02625
12. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 10029064
13. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229 11309270
14. Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 21:5427-5440 10.1038/sj.onc.1205600
15. Esteller M (2003) Profiling aberrant DNA methylation in hematologic neoplasms: A view from the tip of the iceberg. Clin Immunol 109:80-88 10.1016/S1521-6616(03)00208-0
16. Galm O, Esteller M (2004) Beyond genetics - the emerging role of epigenetic changes in hematopoietic malignancies. Int J Hematol 80:120-127 10.1532/IJH97.04075
17. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R (2004) DNA methylation changes in multiple myeloma. Leukemia 18:1687-1692 10.1038/sj.leu.2403434
18. Gilbert J, Gore SD, Herman JG, Carducci MA (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589-4596 10.1158/ 1078-0432.CCR-03-0297
19. Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542 10.1182/blood-2002-02-0492
20. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195-5199 7585573
21. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088 9058730
22. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333 9746770
23. Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340:1649-1660 10.1056/NEJM199905273402107
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826 10.1073/ pnas.93.18.9821
25. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875 10.1073/pnas.95.12.6870
26. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054 10.1056/ NEJMra023075
27. Issa JP, Baylin SB, Herman JG (1997) DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 11(Suppl 1):S7-S11 9130685
28. Issa JP (2003) Decitabine. Curr Opin Oncol 15:446-451 10.1097/ 00001622-200311000-00007
29. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640 10.1182/blood-2003-03-0687
30. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163-167 10.1038/5947
31. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428 10.1038/nrg962
32. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98:522-528 10.1002/ cncr.11543
33. Katzenellenbogen RA, Baylin SB, Herman JG (1999) Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93:4347-4353 10361133
34. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157-162 10.1038/35101031
35. Laird PW (2003) Early detection: The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253-266 10.1038/nrc1045
36. Leone G, Teofili L, Voso MT, Lubbert M (2002) DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 87:1324-1341 12495905
37. Liu S, Shen T, Rush LJ, Becknel B, Klisovic MI, Whitman SP, Vukosavljevic T, Byrd JC, Plass C, Marcucci G (2003) AML1/ETO associates with DNA methyltransferase I (DNMT1) in inducing transcriptional repression of the AML1-target gene interleukin-3 (IL-3). Blood 102:218a
38. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051-1062 10.1056/NEJM199909303411407
39. Lubbert M (2000) DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: Clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 249:135-164 10802943
40. Melki JR, Vincent PC, Clark SJ (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59:3730-3740 10446989
41. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692 10.1038/nm0795-686
42. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63:1114-1121 12615730
43. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990 9531610
44. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A (2004) Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104:2492-2498 10.1182/blood-2004-03-0954
45. Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, Carbone A, Gaidano G (2004) Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89:154-164 15003890
46. Rountree MR, Bachman KE, Herman JG, Baylin SB (2001) DNA methylation, chromatin inheritance, and cancer. Oncogene 20:3156-3165 10.1038/ sj.onc.1204339
47. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440 10.1200/ JCO.2002.04.117
48. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP (2001) Methylation profiling in acute myeloid leukemia. Blood 97:2823-2829 10.1182/blood.V97.9.2823
49. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF (2000) Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92:1303-1307 10.1093/jnci/ 92.16.1303
50. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962 10694544
51. Willemze R, Suciu S, Archimbaud E, Muus P, Stryckmans P, Louwagie EA, Berneman Z, Tjean M, Wijermans P, Dohner H, Jehn U, Labar B, Jaksic B, Dardenne M, Zittoun R (1997) A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 11(Suppl 1):S24-S27
52. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28:29-35 10.1038/88225